drugset / Trial / NCT04047004

Adjuvant PIPAC in Gastric Cancer Patients

NCT04047004 ↗

Phase 1 Completed 20 enrolled Michael Bau Mortensen
NaSingle-groupOpen-labelOther

Summary

In this study patients will be offered intraperitoneal atomized chemotherapy as a supplement to the standard treatment of high-risk gastric cancer (laparoscopic removal of the stomach). Two commercially available oncologic drugs will be used (doxorubicin and cisplatin).

Timeline

Start
2020-03-11
Primary completion
2022-06-30
Completion
2022-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 10.5 mg/m2 Other
Subject Doxorubicin Other / unclassified 2.1 mg/m2 Other